FDA Downgrades Opioid Oxygen Monitor to Class II
Published Date: 6/30/2026
Rule
Summary
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Class II Reclassification Speeds Access
FDA has classified the monitor for opioid-induced impairment of oxygenation as Class II (special controls). This final order is effective June 30, 2026 (and the classification was applicable on March 31, 2023), and FDA says the change provides reasonable assurance of safety and effectiveness while enhancing patients' access by reducing regulatory burdens.
Easier Route to Market for Makers
Because FDA placed this monitor into Class II via the De Novo process, the device can serve as a predicate for future devices so other sponsors can use the less burdensome 510(k) pathway instead of De Novo or premarket approval. FDA states this will enhance patient access in part by reducing regulatory burdens and could lower costs and delays for companies making these monitors.
Special Controls Require Testing and Documentation
Manufacturers of these monitors must meet detailed special controls, including clinical performance data (accuracy, sensitivity, specificity), software verification and validation with hazard analysis, non-clinical sensor performance testing, usability assessment, biocompatibility, and electromagnetic and safety testing. Compliance with these special controls is required for the device to remain in Class II and avoid automatic placement in Class III.
Labels Must Include Overdose Warnings and Info
Labeling for these monitors must include a summary of clinical validation (including sensitivity, specificity, positive and negative predictive values by subpopulation), principles of sensor operation, information on preventing, recognizing, and treating an overdose, warnings that the device may not distinguish other conditions, warnings against overreliance, and a warning about the need for supervised use with awareness of countermeasures such as naloxone.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19921, Determination That SULFADIAZINE (Sulfadiazine) Tablet, 500 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 500 mg sulfadiazine tablet wasn’t taken off the market because it was unsafe or didn’t work. This means generic drug makers can now apply to sell their versions, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back.
2026-19850, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503
The FDA is asking for public feedback on how it collects info about food and color additives, including their labels and safety petitions. This affects companies that want to add or change ingredients in food and how they submit their paperwork electronically. Comments are due by October 29, 2026, and the process helps keep food safe without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-13139, Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
Next: 2026-13153, Magnuson-Stevens Fishery Conservation and Management Act Provisions; Fisheries of the Northeastern United States; Northeast Multispecies Fishery; Amendment 25 (Revised)
Starting June 30, 2026, new rules update how Atlantic cod stocks are managed in the Northeast multispecies fishery. These changes affect both commercial and recreational fishers by setting fresh limits and protections to stop overfishing and help cod populations bounce back. The goal? Keep fishing fun and sustainable while supporting a $40 million industry.